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Psoriasis and the Risk of Major Cardiovascular Events:
Cohort Study Using the Clinical Practice Research
Datalink
Rosa Parisi1, Martin K. Rutter2,3, Mark Lunt4, Helen S. Young5, Deborah P.M. Symmons4,6,
Christopher E.M. Grifﬁths5, Darren M. Ashcroft1 and on behalf of the Identiﬁcation and Management of
Psoriasis Associated ComorbidiTy (IMPACT) project team
The association between psoriasis and risk of major cardiovascular (CV) events (myocardial infarction, acute
coronary syndrome, unstable angina, and stroke) is unclear. A cohort study with 48,523 patients with psoriasis
and 208,187 controls was conducted. During a median follow-up of 5.2 years, 1,257 patients with psoriasis (2.59%)
had a major CV event, compared with 4,784 controls (2.30%). In the multivariable analysis, inﬂammatory arthritis
hazard ratio (HR) 1.36 (1.18–1.58), diabetes HR 1.18 (1.06–1.31), chronic kidney disease HR 1.18 (1.07–1.31),
hypertension HR 1.37 (1.29–1.45), transient ischemic attack HR 2.74 (2.41–3.12), atrial ﬁbrillation HR 1.54 (1.36–1.73),
valvular heart disease HR 1.23 (1.05–1.44), thromboembolism 1.32 (1.17–1.49), congestive heart failure HR 1.57
(1.39–1.78), depression HR 1.16 (1.01–1.34), current smoker HR 2.18 (2.03–2.33), age (year) HR 1.07 (1.07–1.07), and
male gender HR 1.83 (1.69–1.98) were statistically signiﬁcant for the risk of major CV events. The age- and gender-
adjusted HRs of a major CV event for psoriasis were 1.10 (1.04–1.17) and for severe psoriasis 1.40 (1.07–1.84),
whereas the fully adjusted HRs were attenuated to 1.02 (0.95–1.08) and 1.28 (0.96–1.69). In conclusion, neither
psoriasis nor severe psoriasis were associated with the short-to-medium term (over 3–5 years) risk of major
CV events after adjusting for known cardiovascular disease risk factors.
Journal of Investigative Dermatology (2015) 135, 2189–2197; doi:10.1038/jid.2015.87; published online 9 April 2015
INTRODUCTION
Psoriasis is a chronic skin disorder, now recognized as one of
the most common immune-mediated diseases (Grifﬁths and
Barker, 2007) with a prevalence between 0.91% and 8.5% in
Western countries (Parisi et al., 2013). The severity of
psoriasis can range from a mild disease involving small
body surface area to extensive skin involvement and, in many
cases, has a major impact on people’s quality of life (Rapp
et al., 1999; Gelfand et al., 2004; Stern et al., 2004). Psoriasis
often coexists with other disorders, perhaps due to chronic
inﬂammation (Grifﬁths and Barker, 2007), such as obesity
(Naldi et al., 2005; Setty et al., 2007), hypertension, hyper-
lipidemia (Neimann et al., 2006), and diabetes (Lee et al.,
2014), which are associated with an increased risk of
cardiovascular disease (CVD). The main hypothesis for an
association between psoriasis and CVD is that increased
systemic inﬂammation, as occurs in psoriasis, exacerbates
other chronic inﬂammatory diseases including athero-
sclerosis, which could lead to myocardial infarction (MI)
or stroke (Grifﬁths and Barker, 2007; Boehncke et al., 2011).
The possible link between psoriasis and CVD is complex for
several reasons: psoriasis is associated with unhealthy life-
styles (increased likelihood of smoking, little physical activity,
and obesity; Nijsten and Wakkee, 2009); a higher prevalence
of CVD risk factors (such as, diabetes, hypertension, and
hyperlipidemia (Neimann et al., 2006)); and therapies for
psoriasis that may increase (e.g., ciclosporin (Nijsten and
Wakkee, 2009)) or decrease (e.g., methotrexate (Westlake
et al., 2010)) the CVD risk; all aspects which may confound
the association between the two disorders.
Conﬂicting evidence exists regarding the relationship
between psoriasis and CVD. A number of studies have
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suggested an increased risk of fatal and non-fatal CVD events
in patients with psoriasis after controlling for several major
CVD risk factors (Mallbris et al., 2004; Gelfand et al., 2006;
Ludwig et al., 2007; Kaye et al., 2008; Gelfand et al., 2009;
Mehta et al., 2010; Ahlehoff et al., 2011, 2012; Lin et al.,
2011; Li et al., 2012; Dregan et al., 2014). In contrast, other
studies have concluded that psoriasis is not an independent
risk factor for CVD (Brauchli et al., 2009; Wakkee et al., 2010;
Stern and Huibregtse, 2011; Dowlatshahi et al., 2013). A
recent systematic review of epidemiological studies suggested
a possible association between severe psoriasis and CVD but
acknowledged that the majority of studies failed to adequately
adjust for important risk factors (Samarasekera et al., 2013).
Inﬂammatory arthritis, a common co-morbidity in patients
with psoriasis and a recognized risk factor for CVD (Han et al.,
2006; Symmons and Gabriel, 2011; John and Kitas, 2012),
has rarely been considered as a possible confounder. It is also
important to note that, in many studies using electronic
medical record databases, severe psoriasis is typically deﬁned
by exposure to systemic or biologic therapies, which may also
be used to treat inﬂammatory arthritis. This raises the
possibility of misclassiﬁcation of severe psoriasis when not
taking account of the presence of inﬂammatory arthritis.
Furthermore, little consideration has been given in earlier
studies to the time-varying nature for the development of risk
factors or the severity of psoriasis.
Given these premises, a large population-based cohort
study was undertaken in order to investigate whether psoriasis
is independently associated with an increased risk of major
cardiovascular (CV) events (MI, acute coronary syndrome
(ACS), unstable angina, and stroke) when taking into account
relevant CVD risk factors.
RESULTS
Between 1994 and 2009, 48,523 patients with psoriasis and
208,187 controls met the inclusion criteria. Table 1 sum-
marizes the demographic characteristics of the included
patients. Patients with psoriasis had a higher prevalence of
the majority of risk factors compared with the control group at
baseline (Table 1) and a higher prevalence of all time-varying
risk factors at the end of follow-up except for atrial ﬁbrillation,
transient ischaemic attack, and congestive heart failure
(Table 2). In particular, inﬂammatory arthritis was present in
2.39% of patients with psoriasis and 0.98% of the controls at
baseline and in 4.69% of the patients with psoriasis and
1.38% of the controls by the end of follow-up. In addition, at
baseline, there were 1.03% of patients with psoriasis
receiving phototherapy, systemic, or biologic therapies,
which increased to 4.29% patients by the end of follow-up.
Of note, 50.62% of patients receiving systemic or biologic
therapies also had a diagnosis of inﬂammatory arthritis by the
end of follow-up. Methotrexate was the most commonly used
systemic treatment used in patients with psoriasis (Table 3).
During a median follow-up of 5.2 years, 1,257 patients with
psoriasis (2.59%) had a major CV event, compared with 4,784
controls (2.30%). The unadjusted incidence rate of a major
CV event per 1,000 person-years was higher in the psoriasis
group than the control group (4.13 per 1,000 person-years
(95% conﬁdence interval (CI): 3.91–4.36) and 3.87 per 1,000
person-years (95% CI: 3.76–3.98), respectively; Table 4).
Investigating the assumption of proportionality by using
Schoenfeld residuals revealed time-varying effects for hyper-
tension, transient ischaemic attack, atrial ﬁbrillation, and
gender. However, allowing these variables to have different
effects for the ﬁrst 3 years of follow-up compared with the
later follow-up removed the non-proportionality (P= 0.12).
The age-and gender-adjusted hazard ratio (HR) of major CV
events associated with the presence of psoriasis was 1.10
(95% CI: 1.04–1.17), but this was attenuated and became
nonsigniﬁcant in the multivariate model (HR 1.02 (95% CI:
0.95–1.08)). The presence of severe psoriasis was associated
with an increased risk of major CV events in the age-and
gender-adjusted analysis (HR 1.40 (95% CI: 1.07–1.84)), but
in the fully adjusted model the HR was above 1 but not
signiﬁcant (HR 1.28 (95% CI: 0.96–1.69)). In the multivariate
analysis, the following risk factors (inﬂammatory arthritis HR
1.36 (95% CI: 1.18–1.58); diabetes HR 1.18 (95% CI: 1.06–
1.31); chronic kidney disease HR 1.18 (95% CI: 1.07–1.31);
hypertension HR 1.37 (95% CI: 1.29–1.45); transient ischae-
mic attack HR 2.74 (95% CI: 2.41–3.12); atrial ﬁbrillation HR
1.54 (95% CI: 1.36–1.73); valvular heart disease HR 1.23
(95% CI: 1.05–1.44); thromboembolism HR 1.32 (95% CI:
1.17–1.49); congestive heart failure HR 1.57 (95% CI: 1.39–
1.78); depression HR 1.16 (95% CI: 1.01–1.34); current
smoker HR 2.18 (95% CI: 2.03–2.33); age (year) HR 1.07
(95% CI: 1.07–1.07); and male gender HR 1.83 (95% CI:
1.69–1.98)) were signiﬁcantly related to the risk of major CV
events (Table 5), whereas hyperlipidemia was not (HR 1.04
(95% CI: 0.96–1.11)). A fully adjusted model with an
interaction between psoriasis or severe psoriasis and age
was ﬁtted; however, the interaction terms were nonsigniﬁcant
(P=0.40 or P= 0.25, respectively) and for this reason were
not included in the ﬁnal model.
Results from sensitivity analyses did not change the main
ﬁndings. Similar results were obtained when adjusting the
model for different set of risk factors (Supplementary Table S1
online) or when including body mass index (BMI) and index
of multiple deprivation (IMD) as additional risk factors in the
multivariate model (Table 6). Likewise, results from the
analyses of patients with at least one general practice visit
per year, patients with at least 6-month follow-up, or results
that took into account patients exposed to methotrexate,
ciclosporin, or oral retinoids were consistent with the main
ﬁndings (Table 6). Finally, a nested analysis including patients
from the Clinical Practice Research Datalink (CPRD) linked to
the Ofﬁce for National Statistics (ONS) mortality data and
patient-level socioeconomic status (IMD) also yielded similar
results to the main ﬁndings (Table 6).
DISCUSSION
Our ﬁndings suggest that patients with psoriasis have an
increased prevalence of comorbidities associated with CVD;
however, neither psoriasis nor severe psoriasis was signiﬁ-
cantly associated with the short-to-medium term risk (over 3–
5 years) of major CV events when taking into account other
established risk factors for CVD. In particular, the risk of a
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major CV event was 36% higher in patients with psoriasis
who also had inﬂammatory arthritis compared with those
who did not.
Consistent with other studies, we found a higher prevalence
of CVD risk factors in patients with psoriasis (Gelfand et al.,
2006; Neimann et al., 2006; Kaye et al., 2008). Our ﬁndings
are in line with those reported by others who did not ﬁnd an
overall higher risk of MI associated with psoriasis (Brauchli
et al., 2009; Wakkee et al., 2010). However, compared with
those studies, our research has important strengths: (a) our
sample size was large (Wakkee et al., 2010); (b) psoriasis
cases were identiﬁed on the bases of diagnosis and treatment
received (Brauchli et al., 2009); and (c) we accounted for
important confounders including inﬂammatory arthritis
(Brauchli et al., 2009; Wakkee et al., 2010).
Our ﬁndings are different from several previous studies
exploring risk of major CV events. Ogdie et al. (2015), using
The Health Improvement Network, reported an increased risk
of major adverse CV events in patients with either mild or
severe psoriasis. The cohort of patients with psoriasis
identiﬁed by Ogdie et al. (2015) had possibly longer disease
duration compared with patients identiﬁed in our cohort
because of different study designs (prevalent versus incident
cohort). However, a prevalent cohort is associated with the
problem of left censoring. For instance, patients with the most
severe psoriasis or CVD may have already died before cohort
Table 1. Characteristics of patients at baseline
Psoriasis patients Controls P-values
No. 48,523 208,187
Demographics
Men (%) 22,932 (47.26) 88,998 (42.75) o0.001
Women (%) 25,591 (52.74) 119,189 (57.25)
Median age (IQR) 47 (25) 48 (26) o0.001
Comorbidities/covariates
Severe psoriasis (%) 503 (1.03) — —
Inﬂammatory arthritis (%) 1,158 (2.39) 2,040 (0.98) o0.001
Chronic kidney disease (%) 444 (0.92) 1,991 (0.96) 0.398
Hypertension (%) 7,467 (15.39) 31,079 (14.93) 0.011
Hyperlipidemia (%) 4,131 (8.51) 16,203 (7.78) o0.001
Depression (baseline) (%) 2,096 (4.32) 7,113 (3.42) o0.001
Smoking status
Never-smoker (%) 15,551 (32.05) 79,214 (38.05) o0.001
Ex-smoker (%) 12,948 (26.68 ) 52,656 (25.29)
Current smoker (%) 15,379 (31.69) 52,435 (25.19)
Unknown smoking status (%) 4,645 (9.57) 23,882 (11.47)
Body mass index1, mean± SD 27.40±5.63 26.73±5.36 o0.001
o20—underweight (%) 1,966 (4.05) 9,503 (4.56) o0.001
20–24.9—normal (%) 11,879 (24.48) 55,197 (26.51)
25–29.9—overweight (%) 13,362 (27.54) 54,065 (25.97)
30+—obese (%) 9,880 (20.36) 34,337 (16.49)
Unknown BMI (%) 11,436 (23.57) 55,085 (26.46)
IMD score2(%)
1 6,808 (14.03) 29,898 (14.36) 0.005
2 6,553 (13.50) 28,763 (13.82)
3 5,605 (11.55) 23,789 (11.43)
4 5,186 (10.69) 21,190 (10.18)
5 4,083 (8.41) 17,309 (8.31)
Unknown (%) 20,288 (41.81) 87,238 (41.90)
Abbreviations: BMI, body mass index; IMD, index of multiple deprivation; IQR, interquartile range.
1BMI is calculated as weight in kilograms divided by height in meters squared.
2IMD is presented in quintiles with one being the most afﬂuent area and ﬁve the most deprived.
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entry, and hence such studies only address the question as to
what happens to patients who have already survived with
their psoriasis. In contrast with our study, Dregan et al. (2014),
using CPRD, reported an increased and signiﬁcant risk of
coronary heart disease in patients with severe psoriasis.
However, they may have misclassiﬁed severe psoriasis on the
basis of treatments received without considering co-morbid
inﬂammatory arthritis. Ahlehoff et al. (2011), using a Danish
nationwide database, suggested an increased risk of CVD in
patients with severe psoriasis with and without psoriatic
arthritis. However, patients with severe psoriasis were
identiﬁed using hospitalization for psoriasis or psoriatic
arthritis, which could be subject to potential surveillance
bias (Ahlehoff et al., 2011). Moreover, comorbidities were
assigned using prescribed treatments rather than diagnostic
codes, which could lead to potential misclassiﬁcation. Other
differences compared with previous studies include the wider
range of risk factors examined in our analyses (Ahlehoff et al.,
2011; Dregan et al., 2014; Ogdie et al., 2015), modeling these
to account for the development of new risk factors over time
(Ahlehoff et al., 2011; Dregan et al., 2014; Ogdie et al., 2015);
and examining the severity of psoriasis as a time-varying
covariate, so that patients with severe psoriasis become at risk
when they start receiving phototherapy, systemic therapy, or
biologic therapies (rather than identiﬁed as whether they have
ever been exposed to systemic treatment and all time under
observation classed as severe psoriasis; Dregan et al., 2014).
Strengths and limitations of this study
Observational studies are susceptible to bias and confound-
ing. In this study, possible selection bias, information bias,
and detection bias, which occur, for example, when patients
with a skin disease are more likely to be diagnosed with
another disease while visiting their physician for their skin
condition (Wakkee et al., 2010), were minimized, as patients
with and without psoriasis came from the same database; they
were selected from the same general practice and during
the same time-window, respectively. Furthermore, potential
detection bias was examined via sensitivity analysis by
Table 2. Characteristics of patients at the end of follow-up for time-varying covariates
Psoriasis
patients Controls P-values
Mild
psoriasis
patients Controls P-values
Severe
psoriasis
patients Controls P-values
No. 48,523 208,187 46,439 200,226 2,084 7,961
Severe psoriasis (%) 2,084 (4.29) — — — 2,084 —
Inﬂammatory arthritis (%) 2,275 (4.69) 2,874 (1.38) o0.001 1,220 (2.63) 2,737 (1.37) o0.001 1,055 (50.62) 137 (1.72) o0.001
Diabetes (%) 2,806 (5.78) 9,767 (4.69) o0.001 2,618 (5.64) 9,305 (4.65) o0.001 188 (9.02) 462 (5.80) o0.001
Chronic kidney disease (%) 2,400 (4.95) 9,509 (4.57) o0.001 2,241 (4.83) 9,146 (4.57) 0.017 159 (7.63) 363 (4.56) o0.001
Hypertension (%) 12,140 (25.02) 48,596 (23.34) o0.001 11,481 (24.72) 46,628 (23.29) o0.001 659 (31.62) 1,968 (24.72) o0.001
Hyperlipidemia (%) 6,232 (12.84) 23,239 (11.16) o0.001 5,912 (12.73) 22,169 (11.07) o0.001 320 (15.36) 1,070 (13.44) 0.024
Atrial ﬁbrillation (%) 877 (1.81) 3,605 (1.73) 0.251 827 (1.78) 3,470 (1.73) 0.478 50 (2.40) 135 (1.70) 0.033
Transient ischaemic attack (%) 395 (0.81) 1,601 (0.77) 0.309 382 (0.82) 1,534 (0.77) 0.212 13 (0.62) 67 (0.84) 0.319
Congestive heart failure (%) 719 (1.48) 2,733 (1.31) 0.004 681 (1.47) 2,660 (1.33) 0.021 38 (1.82) 73 (0.92) o0.001
Thromboembolism (%) 1,212 (2.50) 4,864 (2.34) 0.035 1,128 (2.43) 4,678 (2.34) 0.235 84 (4.03) 186 (2.34) o0.001
Valvular heart disease (%) 587 (1.21) 2,352 (1.13) 0.136 559 (1.20) 2,249 (1.12) 0.141 28 (1.34) 103 (1.29) 0.859
Smoking status
Never-smoker (%) 15,232 (31.39) 80,541 (38.69) o0.001 14,563 (31.36) 77,484 (38.70) o0.001 669 (32.10) 3,057 (38.40) o0.001
Ex-smoker (%) 18,814 (38.77) 73,056 (35.09) 17,920 (38.59) 69,979 (34.95) 894 (42.90) 3,077 (38.65)
Current smoker (%) 13,344 (27.50) 46,846 (22.50) 12,841 (27.65) 45,160 (22.55) 503 (24.14) 1,686 (21.18)
Unknown smoking status (%) 1,133 (2.33) 7,744 (3.72) 1,115 (2.40) 7,603 (3.80) 18 (0.86) 141 (1.77)
Table 3. Phototherapy, systemic, or biologic
treatments received by patients with psoriasis
Psoriasis patients
No. 2,0841
Methotrexate (%) 1,486 (71.31)
PUVA/Phototherapy (%) 404 (19.39)
Ciclosporin (%) 215 (10.32)
Oral retinoids (%) 128 (6.14)
Hydroxycarbamide (%) 49 (2.35)
Etanercept (%) 9 (0.43)
Adalimubab (%) 8 (0.38)
Fumaric Acid (%) 2 (0.1)
Inﬂiximab (%) 1 (0.05)
1Percentages do not add up to 100% because patients could have received
more than one treatment.
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selecting only patients who had at least one general practice
visit per year. Our ﬁndings were consistent after multiple
sensitivity and subgroup analyses. Several additional strengths
can be identiﬁed in our study. First, important confounders,
including traditional and non-traditional CVD risk factors,
were taken into account in order to investigate the association
between psoriasis and major CV events, in particular
inﬂammatory arthritis. Second, we present a large
Table 4. Event rates and incidence rates of major cardiovascular events in patients with psoriasis and controls and
by psoriasis severity
Psoriasis
patients Controls
Mild psoriasis
patients
Controls to
mild psoriasis
Severe psoriasis
patients
Controls to
severe psoriasis
No. 48,523 208,187 48,020 206,000 2,084 7,961
Follow-up in years,
median (IQR)
5.48 (5.55) 5.12 (5.32) 5.33 (4.28) 5.00 (5.30) 3.59 (4.23) 3.65 (4.36)
Person-years 304,442 1,237,895 295,283 1,202,902 9,159 34,992
Number of major CV
events (%)
1,257 (2.59) 4,784 (2.30) 1,203 (2.51) 4,644 (2.25) 54 (2.59) 140 (1.76)
Incidence per 1,000
person-years (95% CI)
4.13 (3.91; 4.36) 3.87 (3.76; 3.98) 4.07 (3.85; 4.31) 3.86 (3.75; 3.97) 5.90 (4.52; 7.70) 4.00 (3.39; 4.72)
Abbreviations: CI, conﬁdence interval; CV, cardiovascular; IQR, interquartile range.
Psoriasis severity was modeled as a time-varying covariate.
Table 5. Hazard ratios associated with psoriasis and potential confounding variables for the risk of incident major
cardiovascular events in Cox regression models
Age and gender adjusted HR (95% CI) P-value Multivariate HR (95% CI) P-value
Psoriasis1 1.10 (1.04; 1.17) 0.002 1.02 (0.95; 1.08) 0.606
Severe psoriasis1 1.40 (1.07; 1.84) 0.015 1.28 (0.96; 1.69) 0.089
Inﬂammatory arthritis 1.48 (1.28; 1.70) o0.001 1.36 (1.18; 1.58) o0.001
Diabetes 1.31 (1.18; 1.45) o0.001 1.18 (1.06; 1.31) 0.002
Chronic kidney disease 1.18 (1.18; 1.45) 0.001 1.18 (1.07; 1.31) 0.001
Hypertension 1.37 (1.30; 1.44) o0.001 1.37 (1.29; 1.45) o0.001
Hyperlipidemia 1.09 (1.01; 1.17) 0.020 1.04 (0.96; 1.11) 0.346
Transient ischaemic attack 3.21 (2.82; 3.65) o0.001 2.74 (2.41; 3.12) o0.001
Atrial ﬁbrillation 1.85 (1.65; 2.07) o0.001 1.54 (1.36; 1.73) o0.001
Valvular heart disease 1.49 (1.28; 1.75) o0.001 1.23 (1.05; 1.44) 0.012
Thromboembolism 1.38 (1.22; 1.56) o0.001 1.32 (1.17; 1.49) o0.001
Congestive heart failure 1.99 (1.77; 2.24) o0.001 1.57 (1.39; 1.78) o0.001
Depression 1.30 (1.13; 1.50) o0.001 1.16 (1.01; 1.34) 0.037
Age 1.07 (1.07; 1.07) o0.001 1.07 (1.07; 1.07) o0.001
Male 1.87 (1.78; 1.97) o0.001 1.83 (1.69; 1.98) o0.001
Never smoker Reference
Ex-smoker 1.18 (1.11; 1.26) o0.001 1.18 (1.10; 1.25) o0.001
Current smoker 2.22 (2.07; 2.38) o0.001 2.18 (2.03; 2.33) o0.001
Unknown 1.34 (1.19; 1.51) o0.001 1.23 (1.09; 1.40) 0.001
Calendar year 0.95 (0.94; 0.95) o0.001 0.95 (0.94; 0.96) o0.001
Abbreviations: CI, conﬁdence interval; HR, Hazard ratio.
1The variable “psoriasis” identiﬁes all patients with psoriasis, both mild and severe. The reference group for this variable is the group of controls (patients
without psoriasis). The variable “severe psoriasis”, which is modeled as a time-varying covariate, identiﬁes patients who are (i) severe at baseline or (ii)
patients who have mild psoriasis at baseline but develop severe psoriasis during follow-up. The variable “severe psoriasis” is entered into the model (both
univariate and multivariate) together with the general variable “psoriasis”. Therefore, when both variables “psoriasis” and “severe psoriasis” are included into
the model, the variable “severe psoriasis” will identify patients with severe psoriasis against controls. Therefore, the reference population for the “severe
psoriasis” variable is the group of controls.
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population-based study representative of the UK. Third, only
patients with at least a diagnostic code of psoriasis and a
treatment for psoriasis were included in the cohort to
minimize the risk of disease misclassiﬁcation. Fourth, more
advanced methodology was employed such as the use of the
shared frailty model, which takes better account of the
matched nature of the data and the use of time-varying
covariates.
Some potential limitations also need to be taken into
account. As this was an observational study, the risk of
residual confounding should be considered. Given that CPRD
is a primary care database, diagnoses of psoriasis were not
necessarily conﬁrmed by dermatologists; phototherapy,
systemic therapy, or biologics were used as a surrogate to
assess disease severity rather than more objective measures,
such as the psoriasis area and the severity index or the
body surface area covered by psoriasis. The group of patients
having or developing severe psoriasis could be under-
powered to investigate the end point of interest. Our duration
of follow-up was on average over 5 years for patients
with psoriasis and over 3 years for those who developed
severe psoriasis while under observation. However, chronic
inﬂammation may take longer to develop adverse CV
outcomes, and, as such, future studies with longer follow-up
are recommended.
Furthermore, because of the limited number of patients
exposed to biologic treatments, it was not possible to
investigate whether biologic therapy potentially reduces the
risk of major CV events. Our study was speciﬁcally designed
to investigate whether psoriasis is independently associated
with the risk of major CV events, and in order to minimize the
risk of bias we excluded patients from our cohort with a prior
history of CVD or diabetes.
CONCLUSIONS AND IMPLICATIONS
Patients with psoriasis have an increased prevalence of
CV risk factors and co-morbid conditions associated with
CVD. However, neither psoriasis nor severe psoriasis was
related to a short-to-medium term (over 3–5 years) risk of
major CV events (MI, ACS, unstable angina, or stroke) after
adjusting for important CV risk factors. The co-occurrence of
inﬂammatory arthritis and psoriasis was an independent risk
factor for major CV events. This implies that patients with
psoriasis should be screened for traditional risk factors, and
these should be treated according to local guidelines. Patients
with inﬂammatory arthritis are at increased risk of CVD, and
this may be an additional reason to minimize the patient’s
cumulative inﬂammatory burden.
MATERIALS AND METHODS
Study design
An inception cohort study was conducted using the CPRD. The
CPRD comprises medical records from general practices in the UK
holding the demographic and the medical history of patients
including treatments, clinical events, test results, and referrals to
hospitals. On September 2012, data were available for 652 practices
and over 12 million patients. In CPRD, clinical diagnoses are
recorded using hierarchical clinical Read codes (Robinson et al.,
1997). Numerous studies have demonstrated the validity of CPRD for
observational research studies (Jick et al., 1991; Herrett et al., 2010),
including studies on psoriasis (Gelfand et al., 2003) and major
CV events (Gulliford et al., 2009; Khan et al., 2010).
The protocol of this study was approved by the CPRD Indepen-
dent Scientiﬁc Advisory Committee (protocol reference number
11_134A). The study is reported according to STROBE guidelines
(Erik von et al., 2007).
Study population
The study population included patients with a ﬁrst diagnosis of
psoriasis between 1 January 1994 and 31 December 2009, who were
20 years or older at the time of the diagnosis. A comparison group of
up to 5 controls per psoriasis patient was selected. Patients from both
cohorts did not have any history of CVD or diabetes before the index
date (ﬁrst diagnosis of psoriasis) or corresponding consulting date
and, in order to capture incident not prevalent cases of psoriasis or
major CV events, all patients had to have at least 2 years prior
registration within their general practice before entry into the study
cohort. The control group consisted of patients who never received a
Table 6. Sensitivity analyses: adjusted hazard ratios associated with psoriasis for the risk of incident major
cardiovascular events
Fully adjusted
model using
multiple
imputation
Fully adjusted model
including BMI and
IMD score using
multiple imputation
Inclusion of
patients with at
least 1 GP visit
per year1
Inclusion of
patients with at
least 6 months
follow-up2
Fully adjusted
model plus a
covariate for
patients on
methotraxete
Fully adjusted model
plus a covariate
for patients on
ciclosporin/oral
retinoids
Linkage of
patients from
CPRD to ONS
and IMD
information3
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Psoriasis 1.02 (0.96; 1.08) 1.02 (0.95; 1.08) 1.02 (0.95; 1.09) 1.01 (0.94; 1.07) 1.02 (0.95; 1.08) 1.02 (0.95; 1.08) 1.02 (0.93; 1.11)
Severe psoriasis 1.29 (0.97; 1.70) 1.30 (0.98; 1.72) 1.32 (0.99; 1.76) 1.26 (0.95; 1.68) 1.33 (0.97; 1.82) 1.28 (0.95; 1.71) 1.10 (0.72; 1.68)
Abbreviations: BMI, body mass index; CI, conﬁdence interval; CPRD, Clinical Practice Research Datalink; GP, general practice; HR, hazard ratio; IMD, index
of multiple deprivation; ONS, ofﬁce for national statistics.
1The analysis included 170,930 patients corresponding to 66.58% of the original sample. Fully adjusted model.
2The analysis included 245,111 patients corresponding to 95.48% of the original sample. Fully adjusted model.
3The analysis included 132,075 patients corresponding to 51.45% of the original sample. Fully adjusted model plus the IMD score.
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diagnostic code for psoriasis. Controls were matched to psoriasis
patients by age, gender, and general practice. We assigned control
patients the same index date as the patients with psoriasis to whom
they were matched. Person-time under observation for each patient
was calculated from the corresponding index date up to the end of
the study, which was the earliest date of the occurrence of a major
CV event (MI, ACS, unstable angina, or stroke), transfer out of the
practice, death date, end of follow-up (31 December 2011) or when
the practice was no longer up to research data quality standards set
by CPRD. Patient consent was not required; all patient data
contained in CPRD is anonymised.
Deﬁnition of exposure
Patients with psoriasis were included if they had their ﬁrst diagnostic
code for psoriasis during 1 January 1994–31 December 2009
and received a recognized treatment for psoriasis (emollients,
topical treatment, phototherapy, systemic therapy, or biologics
(CG153 Psoriasis: NICE guideline; Samarasekera and Smith, 2014)).
Patients were classiﬁed as having severe psoriasis once they had
received a systemic treatment (acitretin, etretinate, ciclosporin,
hydroxycarbamide, methotrexate, and fumaric acid), phototherapy, or
a biologic therapy (etanercept, adalimumab, inﬂiximab, ustekinumab,
and efalizumab); alternatively they were classiﬁed as mild psoriasis.
Outcome of interest
The outcome of interest was fatal, and non-fatal incident major CV
end point including MI, ACS, unstable angina, or stroke. In our main
analysis, the combined CV end point was identiﬁed using Read
codes in CPRD. In sensitivity analysis, we identiﬁed the combined
CV end point in both CPRD and national mortality records (ONS) for
those patients registered in practices that provided linked data
between CPRD and ONS.
Covariates
The following covariates were included in the model and tested in
age-and gender-adjusted or multivariate analyses to investigate the
association between psoriasis and risk of major CV events. Presence
of psoriasis, age, gender, depression, and calendar year were
calculated at baseline, whereas other covariates such as having or
developing severe psoriasis, inﬂammatory arthritis (which included
both diagnostic codes for psoriatic arthritis or rheumatoid arthritis),
diabetes, chronic kidney disease, hypertension, hyperlipidemia,
atrial ﬁbrillation, transient ischaemic attack, congestive heart failure,
thromboembolism, valvular heart disease, and smoking status were
modeled as time-varying covariates. Psoriasis was deﬁned as severe
from the date of the ﬁrst exposure to phototherapy, systemic, or
biologic treatment and was considered severe from that point forward
in time. Smoking status, classiﬁed as current, former, never smoker,
or unknown smoking status, allowed patients to switch from one
smoking class to another during follow-up. Depression was modeled
as a static variable rather than a time-varying covariate because it is not
possible to reliably determine when a depressive episode has resolved
in databases such as CPRD. Additional analyses controlling for BMI
and socioeconomic status (measured by the IMD; Department for
Communities and Local Government, 2010) were conducted as part of
the sensitivity analyses because of the higher levels of missing data.
All code lists used for exposure, and outcome are available for
download from www.clinicalcodes.org (Springate et al., 2014).
Statistical analysis
Continuous variables were summarized as median and interquartile
range. Characteristics at baseline and at the end of follow-up for
time-varying covariates were summarized as proportions by the
exposure group. Event rates for the study outcome and incidence
rates of the combined CV end point per 1,000 person-years with 95%
CIs were calculated for patients with and without psoriasis and
by disease severity. Cox proportional hazard regression was used to
estimate the age-and gender-adjusted HRs and 95% CIs for each
variable, and Cox regression with a shared frailty model was used to
estimate the adjusted HRs and 95% CIs. Schoenfeld residuals were
used to test the assumption of proportionality for individual variables
and the model overall. Three of the risk factors taken into account
contained missing data (Table 1): smoking status, BMI, and the IMD
score. Smoking status was included in the main analysis, and a
category was introduced for the missing values. Because of the high
proportion of missing data BMI and IMD score were included only
in sensitivity analyses. For BMI, an algorithm based on inter-
polation was used for data cleaning and for imputation of values
over time.
Multiple sensitivity analyses were performed on the initial
cohort identiﬁed from CPRD in order to test the robustness of
the results. Different set of risk factors were included in the
fully adjusted model in order to investigate a more complex or
parsimonious model.
Multiple imputation was examined in the sensitivity analyses to
allow individuals with missing BMI and patient-level IMD to be
included. An additional model was ﬁtted including BMI and patient-
level IMD information in the fully adjusted model in order to
investigate possible confounding due to BMI or socioeconomic
status. Other sensitivity analyses were as follows: (a) including only
those patients with at least one general practice visit per year;
(b) including only those patients with at least 6 months of follow-up;
(c) testing for an interaction between the presence of psoriasis or
severe psoriasis with age; and (d) additional adjustment for patients
exposed to methotrexate or for patients exposed to ciclosporin or
oral retinoids. Finally, a nested analysis was carried out to assess
the robustness of the main ﬁndings to potential outcome mis-
classiﬁcation. Approximately 70% of CPRD practices in England
are linked to the ONS, which is a national register of births and
deaths. Patients identiﬁed from CPRD practices linked to the ONS
and who had index date (ﬁrst diagnosis of psoriasis or corresponding
consulting date) between 1 January 1998 and 31 December 2009
were identiﬁed and followed-up until 31 December 2011. As ONS
uses the International Classiﬁcation of Disease (ICD) coding system,
the ICD-9/10 codes corresponding to the combined CV end points
were used (www.clinicalcodes.org; Springate et al., 2014). The
outcome was the ﬁrst event of fatal or non-fatal major CV events (MI,
ACS, unstable angina, or stroke) recorded in CPRD or ONS.
All statistical analyses were performed using Stata v12 (StataCorp,
College Station, TX).
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